Thanks, ROCKY. I understand that one of the patient screening impediments, if you will, is the eye sight parameters required/initial study approved, by the FDA.
Are you observing anywhere a change in those parameters, or does that, if meaningful for the clinicals, mean going back to step one and study re-design approval with the FDA? Thanks.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.